\
&
Contact us
\
&
Contact us
Published on | 1 year ago
Programmes Digital, Industry & Space SemiconductorsPlease note that that the latest amendment of the Chips JU Work Programme 2023-2027 has been adopted.
The following updates for call HORIZON-JU-Chips-2024-1-IA are introduced:
The following updates for call HORIZON-JU-Chips-2024-2-RIA are introduced:
The following updates for call HORIZON-JU-Chips-2024-3-RIA are introduced:
The updated Appendix 3 v6 has already been published on the website, in the “Multiannual Programme 2023-2027: https://www.chips-ju.europa.eu/mawp/
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Digital, Industry & Space AI, data & cloud Deployment: Best use of technologies
The Openverse project hosted last week a high-impact workshop, “National Initiatives and the European Partnership on Virtual Worlds,” aligning stakeholders around the European Commission’s Virtual Worlds strategy. The initiative, rooted in the July 2023 Communication on Web 4.0 and Virtual Worlds, aims to build sustainable, inclus... read more
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.
